Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

2.43
+0.09003.85%
Post-market: 2.39-0.0400-1.65%17:01 EDT
Volume:1.06M
Turnover:2.53M
Market Cap:342.92M
PE:-5.31
High:2.46
Open:2.35
Low:2.26
Close:2.34
52wk High:3.10
52wk Low:1.33
Shares:141.12M
Float Shares:101.18M
Volume Ratio:0.81
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4578
EPS(LYR):-0.4702
ROE:-57.40%
ROA:-19.76%
PB:3.70
PE(LYR):-5.17

Loading ...

ProQR Therapeutics Q1 Basic EPS EUR -0.13

THOMSON REUTERS
·
May 12

ProQR to present Axiomer RNA editing data at upcoming scientific conferences

Reuters
·
May 11

ProQR Therapeutics NV expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 04

ProQR Therapeutics announces annual shareholder meeting

Reuters
·
May 04

ProQR Announces Nomination of DR. Lykke Hinsch Gylvin to Its Board of Directors

THOMSON REUTERS
·
Apr 30

ProQR spotlights AX-0810 milestones at investor and analyst event

Reuters
·
Apr 09

BRIEF-Proqr Announces Partnership With Ginkgo Bioworks And Formation Of Ai Advisory Board

Reuters
·
Apr 08

ProQR partners with Ginkgo Bioworks to scale AI-enabled RNA editing discovery

Reuters
·
Apr 08

ProQR Announces Partnership With Ginkgo Bioworks and Formation of AI Advisory Board

THOMSON REUTERS
·
Apr 08

ProQR Therapeutics Nv - Expects First AI-Discovered Development Candidate to Enter Clinic in 2026

THOMSON REUTERS
·
Apr 08

ProQR Therapeutics Nv - Ginkgo Bioworks Makes Strategic Equity Investment in ProQR

THOMSON REUTERS
·
Apr 08

ProQR Therapeutics to host virtual investor and analyst event; pipeline spotlight to include AX-0810 indication update

Reuters
·
Mar 25

ProQR Therapeutics’ Chief Scientific Officer Gerardus Johannes Platenburg files initial beneficial ownership statement

Reuters
·
Mar 19

ProQR Therapeutics NV Director Domenico Valerio Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

ProQR Therapeutics NV CFO Dennis Hom files initial beneficial ownership statement

Reuters
·
Mar 19

ProQR Therapeutics director Alison Frances Lawton files Form 3 initial beneficial ownership statement

Reuters
·
Mar 19

ProQR Therapeutics NV Director Theresa Heggie files initial beneficial ownership statement

Reuters
·
Mar 19

ProQR Therapeutics NV Director Bart Filius Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

ProQR Therapeutics NV CEO and Director Daniel Anton de Boer files initial beneficial ownership statement

Reuters
·
Mar 19

ProQR Therapeutics NV Director Begona Carreno-Gomez Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19